<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1318">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05143996</url>
  </required_header>
  <id_info>
    <org_study_id>CLN-049-001</org_study_id>
    <secondary_id>2020-005195-35</secondary_id>
    <nct_id>NCT05143996</nct_id>
  </id_info>
  <brief_title>CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)</brief_title>
  <official_title>A Phase 1, Open-label, Preliminary Pharmacokinetics (PK) and Safety Study of CLN-049 (An Fms-like Tyrosine Kinase 3 [FLT3] x Cluster of Differentiation 3 [CD3] Bispecific T Cell Engager) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cullinan Oncology, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cullinan Oncology, LLC</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CLN-049-001 is a Phase 1, open-label, multicenter, first-in-human trial of CLN-049 in&#xD;
      patients with Relapsed/Refractory AML&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will receive a single dose of CLN-049 and will be followed for safety for 28 days.&#xD;
      CLN-049 will be administered IV.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 18, 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of treatment emergent events (TEAEs)</measure>
    <time_frame>28 days</time_frame>
    <description>TEAEs will be defined as adverse events that are reported for the first time following study drug administration for worsening of a pre-existing event after the first dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of CLN-049</measure>
    <time_frame>28 Days</time_frame>
    <description>Maximum drug concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ctrough of CLN-049</measure>
    <time_frame>28 Days</time_frame>
    <description>The observed plasma concentration just prior to the beginning of, or at the end of a dosing interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of CLN-049</measure>
    <time_frame>28 Days</time_frame>
    <description>Time to Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2 of CLN-049</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>28 Days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of CLN-049</measure>
    <time_frame>28 days</time_frame>
    <description>Number of ADA (anti-drug antibodies) positive samples at the end of therapy - minus the number of samples that are positive at baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Relapsed/Refractory AML</condition>
  <arm_group>
    <arm_group_label>Single Ascending Dose (SAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of CLN-049 in patients with Relapsed/Refractory AML</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CLN-049</intervention_name>
    <description>[FLT3] x [CD3] bispecific T cell engager</description>
    <arm_group_label>Single Ascending Dose (SAD)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or females aged &gt; 18 years of age.&#xD;
&#xD;
          2. Willing and able to give written informed consent and adhere to protocol requirements;&#xD;
             written informed consent and any locally required authorization must be obtained from&#xD;
             the patient prior to performing any protocol-related procedures, including screening&#xD;
             evaluations, and serial samples of bone marrow and peripheral blood.&#xD;
&#xD;
          3. Confirmed diagnosis of recurrent or refractory AML as defined below.&#xD;
&#xD;
               1. AML either de novo or secondary that either: are in relapse to standard therapy&#xD;
                  following an initial response or failed primary induction therapy (PIF) with no&#xD;
                  complete response (CR [failed ≥2 induction attempts]) and for whom no other&#xD;
                  approved therapy is available.&#xD;
&#xD;
               2. For adults who have comorbidities that preclude use of intensive induction&#xD;
                  chemotherapy, PIF is defined as AML refractory to one of the following, less&#xD;
                  intensive regimens:&#xD;
&#xD;
             i. Patient has received 2 or more cycles of B-cell lymphoma 2 (bcl-2) inhibitors in&#xD;
             combination with azacitidine, decitabine, or low dose cytarabine.&#xD;
&#xD;
          4. Patient has received, and has progressed, recurred, or is intolerant of approved&#xD;
             therapeutic options that are available, or declines treatment with these therapies.&#xD;
&#xD;
          5. White blood cell (WBC) count at the time of the first dose is &lt; 20,000/uL (microliter)&#xD;
             (hydroxyurea is permitted according to standard institutional practice).&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) performance status is 0 to 2.&#xD;
&#xD;
          7. Toxicities related to prior study therapy should have resolved to Grade 1 or less&#xD;
             according to criteria of NCI CTCAE v5.0, except for alopecia, lymphopenia,&#xD;
             neutropenia, leukopenia, anemia, thrombocytopenia. Patients with chronic but stable&#xD;
             toxicities may be allowed to enroll after agreement between the Investigator and&#xD;
             Sponsor.&#xD;
&#xD;
          8. The patient's laboratory values meet the following criteria:&#xD;
&#xD;
               1. Creatinine clearance (CrCl) as calculated by the Cockcroft-Gault formula (Section&#xD;
                  15.1) must be ≥ 60 mL/min;&#xD;
&#xD;
               2. Total bilirubin ≤ 1.5 × ULN (upper limit of normal). This does not apply for&#xD;
                  patients with confirmed Gilbert's Syndrome, hemolysis, or chronic blood&#xD;
                  transfusions, for whom total bilirubin must be less than 3.0 mg/dL with a&#xD;
                  conjugated bilirubin less than 0.5 mg/dL;&#xD;
&#xD;
               3. AST (aspartate aminotransferase) and ALT (alanine aminotransferase) ≤ 3.0 × ULN&#xD;
                  (upper limit of normal) (unless attributed to leukemic involvement).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of acute promyelocytic leukemia (APL)&#xD;
&#xD;
          2. Active central nervous system (CNS) leukemia. For patients with a history of CNS&#xD;
             leukemia, a lumbar puncture should be performed during screening to exclude the&#xD;
             presence of active CNS involvement.&#xD;
&#xD;
          3. Isolated extramedullary relapse&#xD;
&#xD;
          4. Prior organ allograft&#xD;
&#xD;
          5. Allogeneic hematopoietic transplantation&#xD;
&#xD;
          6. Treatment with any of the following:&#xD;
&#xD;
               1. Radiation therapy (XRT) within 28 days of the first dose of CLN-049, or&#xD;
                  craniospinal XRT within 8 weeks of the first dose of CLN-049, or history of total&#xD;
                  body irradiation (TBI).&#xD;
&#xD;
               2. Prior immunotherapy with checkpoint inhibitors, ≤ 42 days prior to the first dose&#xD;
                  of CLN-049.&#xD;
&#xD;
               3. Prior history of chimeric antigen receptor (CAR-T) cell therapy or other modified&#xD;
                  T cell therapy.&#xD;
&#xD;
               4. Anti-leukemic therapy except hydroxyurea for cytoreduction, and intrathecal&#xD;
                  chemotherapy ≤ 14 days or 5 half-lives, whichever is shorter, prior to the first&#xD;
                  dose of CLN-049.&#xD;
&#xD;
               5. Short-acting hematopoietic growth factors ≤ 7 days prior to the first dose of&#xD;
                  CLN-049&#xD;
&#xD;
               6. Long-acting growth factors ≤ 14 days prior to the first dose of CLN-049.&#xD;
&#xD;
               7. Systemic glucocorticoid therapy (except equivalent of &lt; 10 mg prednisone daily)&#xD;
                  or other immune-suppressive drugs ≤ 14 days prior to the first dose of CLN-049&#xD;
                  (see separate guidelines for patients who are post allogeneic hematopoietic&#xD;
                  transplantation). The transient use of corticosteroids for transfusion&#xD;
                  premedication or the treatment of infusion or transfusion reactions will not be&#xD;
                  considered for this criterion. Topical corticosteroids and steroid eye drops are&#xD;
                  allowed, and will not exclude the patient from eligibility.&#xD;
&#xD;
               8. Prior treatment with a FLT3-directed bispecific molecule, or a FLT3-targeted&#xD;
                  antibody.&#xD;
&#xD;
          7. Currently participating/previously participated in an interventional study and&#xD;
             received an investigational drug within 14 days (or five half-lives, whichever is&#xD;
             longer) prior to the first dose of CLN-049.&#xD;
&#xD;
          8. Patients with concomitant second malignancies requiring active treatment in the past&#xD;
             12 months, or if additional therapy is required or anticipated during study&#xD;
             participation.&#xD;
&#xD;
          9. Patients with any active autoimmune disease or a history of known or suspected&#xD;
             autoimmune disease, or history of a syndrome that requires systemic corticosteroids or&#xD;
             immunosuppressive medications, except for patients with vitiligo, psoriasis (in&#xD;
             consultation with the Sponsor), resolved childhood asthma/atopy or autoimmune thyroid&#xD;
             disorders on stable thyroid hormone supplementation.&#xD;
&#xD;
         10. A serious uncontrolled medical disorder that would impair the ability of the patient&#xD;
             to receive protocol therapy or whose control may be jeopardized by the complications&#xD;
             of this therapy. These criteria include, but are not limited to the following:&#xD;
&#xD;
               1. Uncontrolled airway hyper-reactivity;&#xD;
&#xD;
               2. Type 1 diabetes mellitus. Type 2 diabetes mellitus patients are allowed if&#xD;
                  patient is under stable glycemic control as per Investigator assessment;&#xD;
&#xD;
               3. Uncontrolled, clinically significant pulmonary disease;&#xD;
&#xD;
               4. Requirement for supplemental oxygen;&#xD;
&#xD;
               5. Symptomatic congestive heart failure as per Investigator assessment or documented&#xD;
                  cardiac ejection fraction less than 45%. Note: Patients with prior anthracycline&#xD;
                  exposure or a history of ventricular dysfunction should have a baseline&#xD;
                  assessment of cardiac function with an ejection fraction &gt; 45% and no clinically&#xD;
                  significant pericardial effusion.&#xD;
&#xD;
               6. History of unstable angina or myocardial infarction within six months of the&#xD;
                  first dose of CLN-049;&#xD;
&#xD;
               7. Unstable cardiac arrhythmia or clinically significant ventricular arrhythmia;&#xD;
                  presence of intracardiac defibrillator;&#xD;
&#xD;
               8. Uncontrolled hypertension;&#xD;
&#xD;
               9. History of stroke or cerebral hemorrhage within one year of the first dose of&#xD;
                  CLN-049;&#xD;
&#xD;
              10. Poorly controlled seizure disorder;&#xD;
&#xD;
              11. Recent major surgery within three months of the first dose of CLN-049 (with the&#xD;
                  exception of indwelling catheter or port placement) or major surgery with&#xD;
                  unresolved complications that could interfere with study treatment.&#xD;
&#xD;
         11. Any concurrent condition, therapy, or laboratory abnormality that, in the opinion of&#xD;
             the investigator, might compromise patient safety or interfere with the evaluation of&#xD;
             the safety of the drug.&#xD;
&#xD;
         12. Treatment with systemic antiviral, antibacterial, or antifungal agents for acute&#xD;
             infection within 7 days of the first dose of CLN-049. Use of these agents for&#xD;
             treatment of chronic, controlled infection or as prophylaxis is permitted.&#xD;
&#xD;
         13. Has a history of, or a positive test for Human Immunodeficiency Virus (HIV) 1/2 or&#xD;
             primary immunodeficiency disease such as HIV.&#xD;
&#xD;
         14. Known history of hepatitis B (with positive testing for either hepatitis B surface&#xD;
             antigen [HBsAg] or hepatitis B core Ag), hepatitis C (HCV) infection (with positive&#xD;
             testing for HCV antibody and/or HCV ribonucleic acid [RNA] in serum), or acute&#xD;
             hepatitis A (with positive testing for hepatitis A IgM). Note: patients with chronic&#xD;
             HCV with undetectable viral load defined by sustained virologic response 24 weeks&#xD;
             (SVR24) after completion of anti-hepatitis C treatment.&#xD;
&#xD;
         15. Active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection&#xD;
             including history of positive SARS-CoV-2 testing without subsequent documentation of&#xD;
             negative test results, patients with results that are pending but not yet known, or&#xD;
             patients with suspected active infection based on clinical features&#xD;
&#xD;
         16. History of the following events in conjunction with prior treatment with&#xD;
             immunotherapy: Grade 3 or greater neurotoxicity, ocular toxicity, pneumonitis,&#xD;
             myocarditis, or colitis; liver dysfunction meeting the laboratory criteria for Hy's&#xD;
             Law.&#xD;
&#xD;
         17. Live virus vaccines within 28 days of the first dose of CLN-049, during treatment, and&#xD;
             until the end of last dose of CLN-049.&#xD;
&#xD;
         18. Woman of child-bearing potential (WOCBP) who is pregnant or breast-feeding, plans to&#xD;
             become pregnant within 120 days of last study drug administration, or declines to use&#xD;
             an acceptable method to prevent pregnancy during study treatment and for 120 days&#xD;
             after the last dose of study drug administration (Section 15.2).&#xD;
&#xD;
             A WOCBP is defined as:&#xD;
&#xD;
               1. Not surgically sterile, ie, bilateral tubal ligation, bilateral oophorectomy, or&#xD;
                  complete hysterectomy, or;&#xD;
&#xD;
               2. Not post-menopausal, defined as amenorrhea for ≥ 2 years without an alternative&#xD;
                  medical cause.&#xD;
&#xD;
             Note: Women with amenorrhea for &lt; 2 years and who are not surgically sterile ie, tubal&#xD;
             ligation, bilateral oophorectomy, or complete hysterectomy will only be considered not&#xD;
             to be of reproductive potential if patient have a documented follicle stimulating&#xD;
             hormone (FSH) value in the postmenopausal range.&#xD;
&#xD;
         19. Male patient who plans to father a child or donate sperm within 120 days of last study&#xD;
             drug administration, or who has a partner who is a WOCBP, and declines to use&#xD;
             acceptable method to prevent pregnancy during study treatment and for 120 days after&#xD;
             the last dose of study drug administration (Section 15.2).&#xD;
&#xD;
         20. QT interval corrected for heart rate using Fridericia's formula (QTcF) of ≥ 480&#xD;
             milliseconds.&#xD;
&#xD;
         21. Patient has history of drug-related anaphylactic reactions to any components of&#xD;
             CLN-049. History of Grade 4 anaphylactic reaction to any bispecific molecule or&#xD;
             monoclonal antibody therapy.&#xD;
&#xD;
         22. Known history of prior human anti-human antibody response. Patients will not be&#xD;
             screened for human anti-human antibody prior to study participation.&#xD;
&#xD;
         23. Known active alcohol or drug abuse.&#xD;
&#xD;
         24. Patients who are incapacitated or involuntarily incarcerated.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sandeep Kaur</last_name>
    <phone>7817756212</phone>
    <email>clinops@cullinanoncology.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>David Sallman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Rupa Narayan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Joseph</last_name>
      <email>Rachel.Joseph@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Mohammad Maher Abdul Hay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ghayas Issa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>October 26, 2021</study_first_submitted>
  <study_first_submitted_qc>December 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2021</study_first_posted>
  <last_update_submitted>December 2, 2021</last_update_submitted>
  <last_update_submitted_qc>December 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

